Cellular vaccine therapy for cancer.
Observations that cells of the immune system are able to kill tumor cells both in vitro and in animal models have provided a compelling rationale for pursuit of a strategy whereby immune cells are administered as a therapeutic vaccine to patients with cancer. The successful outcome of this approach depends upon the ability to deliver this therapy in a manner in which a potent immune response is elicited. By harnessing the capacity of dendritic cells that are pivotal in priming the immune response and using gene therapy approaches to optimise the immune response, this may ultimately prove efficacious in the management of human cancer. Promising reports from recent clinical trials suggest that this may well be a realistic goal.
Armstrong
Anne C
AC
Department of Medical Oncology, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Manchester, UK. Aarmstrong@picr.man.ac.uk
Eaton
David
D
Ewing
Joanne C
JC
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D015551:Autoimmunity / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology*; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000517:prevention & control*; D013601:T-Lymphocytes / Q000276:immunology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines